ADMA Biologics Inc $ADMA Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC decreased its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 71.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 79,622 shares of the biotechnology company’s stock after selling 196,333 shares during the quarter. Lisanti Capital Growth LLC’s holdings in ADMA Biologics were worth $1,167,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ADMA. AlphaQuest LLC acquired a new stake in ADMA Biologics in the 3rd quarter worth about $46,000. Arizona State Retirement System lifted its holdings in shares of ADMA Biologics by 1.9% during the 3rd quarter. Arizona State Retirement System now owns 70,623 shares of the biotechnology company’s stock worth $1,035,000 after acquiring an additional 1,307 shares during the period. Kornitzer Capital Management Inc. KS boosted its position in shares of ADMA Biologics by 652.0% in the third quarter. Kornitzer Capital Management Inc. KS now owns 359,985 shares of the biotechnology company’s stock worth $5,277,000 after acquiring an additional 312,115 shares during the last quarter. PFG Investments LLC grew its holdings in ADMA Biologics by 2.8% in the third quarter. PFG Investments LLC now owns 221,515 shares of the biotechnology company’s stock valued at $3,247,000 after purchasing an additional 6,025 shares during the period. Finally, Y Intercept Hong Kong Ltd increased its position in ADMA Biologics by 40.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 105,283 shares of the biotechnology company’s stock worth $1,543,000 after purchasing an additional 30,392 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $28.50.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $17.30 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.13 and a quick ratio of 3.65. The firm’s fifty day moving average price is $18.57 and its 200 day moving average price is $17.04. The company has a market capitalization of $4.12 billion, a price-to-earnings ratio of 20.12 and a beta of 0.47. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business’s revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.15 EPS. On average, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.